Breast Cancer
Conference Coverage
Oral SERD camizestrant prolongs PFS vs. fulvestrant in breast cancer
The investigational selective estrogen receptor degrader showed efficacy in advanced ER+/HER2– breast cancers, including patients with ESR1...
Conference Coverage
Chemotherapy meets its match against aggressive ER+/HER2– breast cancers
Ribociclib plus endocrine therapy resulted in high response rates and double progression-free survival over combo chemotherapy.
Conference Coverage
Potential cause of worse outcomes among Black breast cancer patients found
Tumor microenvironment of metastasis doorways predicted worse outcomes in Black women with residual ER+/HER2– cancer after neoadjuvant...
News
Less than a third of Americans aware of cancer risk from alcohol
Survey also shows low awareness that cancer risk varies by type of drink.
News
Deductibles a threat to more imaging after abnormal mammogram
The ACA does not mandate coverage for additional tests and a biopsy to help determine whether the patient has cancer.
News
Managing trastuzumab deruxtecan adverse events in the real world
Doctor says real-world toxicity experience has been worse than clinical trial data.
Conference Coverage
Whole breast radiation for breast cancer shown to be safe and effective
Whole breast radiation can cut treatment time from 6 weeks down to 3 weeks.
Conference Coverage
Personalized breast screening a step closer to reality
“Several breast cancer risk prediction models have been created, but we believe this is one of the first models designed to guide breast screening...
Conference Coverage
Novel vaccine approach halts disease after 23 years of breast cancer
“The biggest impact so far for me has been that, for the first time in more than a decade, I am not on any medication. That’s really amazing.”
Conference Coverage
How AI is, or will soon be, relevant in radiation oncology
Radiation oncologists at ASTRO 2022 discuss practical applications of AI, and new research findings.